Listar por tema "Glucagon-like peptide 1 agonists; Liver diseases; Metabolic dysfunctionassociated steatotic liver disease; Metabolic health; Pharmacotherapy; Diet; Gut microbiome; Physical exercise; Lifestyle; Non-alcoholic fatty liver disease"
Mostrando ítems 1-1 de 1
-
Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders
(World Journal of Gastroenterology, 28/01/2025)This article comments on the work by Soresi and Giannitrapani. The authors have stated that one of the most novel and promising treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) is the use of ...
